CIRM provides funding across five key areas: Infrastructure, Education, Discovery Research, Translational Research, and Clinical Research. By supporting projects at every stage of development, from initial discovery to clinical trials, CIRM drives progress in regenerative medicine and accelerates innovative therapies to patients.
Check out our portfolio of awards below. Click here to see a list of People We’ve Funded. Click here to see a list of our Funded Institutions.
All CIRM Grants
Search Filters »
Institution |
Researcher name |
Grant Type |
Grant Title |
Award Value |
Salk Institute for Biological Studies |
Prof. Samuel Lawrence Pfaff |
Disease Team Planning |
Motor neuron diseases: Finding cures through basic, translational, and clinical collaboration |
$51,266 |
University of Southern California |
Dr. Mark S Humayun |
Disease Team Planning |
Stem cell based treatment strategy for Age-related Macular Degeneration (AMD) |
$3,088 |
University of California, San Francisco |
Professor Jeffrey Charles Lotz |
Disease Team Planning |
A CIRM Disease Team for the Repair of Traumatically Injured and Arthritic Cartilage |
$33,172 |
University of Southern California |
Dr. David Timothy Woodley |
Disease Team Planning |
Clinical Regenerative Wound Healing With Stem Cells |
$33,626 |
University of California, San Francisco |
Dr. Jeffrey A Bluestone |
Disease Team Planning |
A CIRM Disease Team for the Treatment and Cure of Diabetes |
$55,000 |
University of Southern California |
Dr. Chrysostomos L. Max Nikias |
Major Facilities |
Broad CIRM Facility at USC |
$26,972,500 |
University of California, San Francisco |
Dr. A. Eugene Washington |
Major Facilities |
UCSF CIRM Building |
$34,862,400 |
University of California, Santa Cruz |
Margaret L. Delaney |
Major Facilities |
UC Santa Cruz IBSC Facility |
$7,191,950 |
University of California, Santa Barbara |
Glenn E Lucas |
Major Facilities |
UC Santa Barbara Bio Sciences II |
$3,205,800 |
University of California, Merced |
John O. White |
Major Facilities |
Stem Cell Instrumentation Foundry |
$4,341,321 |
University of California, Los Angeles |
Dr. Gene D. Block |
Major Facilities |
UCLA CIRM Institute |
$19,854,900 |
University of California, Irvine |
Dr. Michael V Drake |
Major Facilities |
UC Irvine CIRM Institute |
$27,156,000 |
University of California, Davis |
Dr. Larry N. Vanderhoef |
Major Facilities |
UC Davis CIRM Institute |
$20,082,400 |
University of California, Berkeley |
Dr. George W. Breslauer |
Major Facilities |
UC Berkeley CIRM Center of Excellence |
$20,183,500 |
Stanford University |
Dr. John L. Hennessy |
Major Facilities |
Stanford SIM1 Building |
$43,578,000 |
Sanford Consortium for Regenerative Medicine |
Edward Holmes |
Major Facilities |
Sanford Consortium for Regenerative Medicine |
$42,827,439 |
Buck Institute for Age Research |
Mary McEachron |
Major Facilities |
CIRM Center of Excellence at Buck Institute for Age Research |
$20,500,000 |
University of California, Los Angeles |
Dr. Bennett G Novitch |
Basic Biology V |
In vitro modeling of human motor neuron disease |
$1,148,758 |
Stanford University |
Dr. Helen M Blau |
Basic Biology V |
Mass Cytometry to Delineate the Human Muscle Stem Cell Hierarchy and Dysfunction in Aging |
$1,175,357 |
Stanford University |
Dr. Marius Wernig MD, PhD |
Basic Biology V |
Mechanisms of human induced neuronal cell reprogramming |
$1,178,370 |
University of California, Irvine |
Dr. Peter J Donovan |
Basic Biology V |
Non-invasive live imaging of stem cell signature metabolic states |
$516,366 |
Palo Alto Veterans Institute for Research |
Dr. Thomas A. Rando |
Basic Biology V |
Molecular regulation of stem cell potency |
$966,510 |
University of California, Merced |
Dr. Kara E McCloskey |
Basic Biology V |
Directed Differentiation of Specialized Endothelial Cells |
$475,686 |
University of California, San Francisco |
Dr. Valerie Marie Weaver |
Basic Biology V |
Biophysical Determinants of Early Embryonic Stem Cell Fate Specification |
$1,186,500 |
California Institute of Technology |
Dr. David Anthony Tirrell |
Basic Biology V |
Engineered matrices for control of lineage commitment in human pancreatic stem cells |
$526,896 |
Salk Institute for Biological Studies |
Ronald Mark Evans |
Basic Biology V |
Metabolically-driven epigenetic changes in iPSC reprogramming |
$1,491,900 |
University of California, San Diego |
Dr. Dianne McKay |
Basic Biology V |
Role of intracytoplasmic pattern recognition receptors in HSC engraftment |
$615,639 |
Stanford University |
Dr. Gary Steinberg |
Basic Biology V |
Paracrine and synaptic mechanisms underlying neural stem cell-mediated stroke recovery |
$1,178,370 |
University of California, San Diego |
Christian Metallo |
Basic Biology V |
Metabolic regulation of cardiac differentiation and maturation |
$1,124,834 |
University of California, Los Angeles |
Dr Samantha J Butler Ph.D. |
Basic Biology V |
Assessing the mechanism by which the Bone Morphogenetic Proteins direct stem cell fate |
$515,730 |
Cedars-Sinai Medical Center |
Paul W Noble |
Basic Biology V |
Innate Immune Regulation of Lung Alveolar Stem Cell Renewal in Mouse and Man |
$617,662 |
Gladstone Institutes, J. David |
Sheng Ding PhD |
Basic Biology V |
A novel druggable mechanism to safeguard stem cell genome |
$1,294,495 |
University of California, San Francisco |
Dr. Mark S. Anderson |
Basic Biology V |
Generation of a functional thymus to induce immune tolerance to stem cell derivatives |
$1,191,000 |
University of California, Irvine |
Dr. Lisa A Flanagan |
Basic Biology V |
Molecular basis of plasma membrane characteristics reflecting stem cell fate potential |
$994,108 |
University of California, San Diego |
Maike Sander |
Basic Biology V |
Defining links between chromatin state and developmental competence |
$1,050,300 |
University of Southern California |
Dr. Denis A Evseenko Dr. |
Basic Biology V |
Promoting survival and countering hypertrophy of pluripotent stem cell (PSC)-derived chondrocytes |
$735,138 |
University of California, Los Angeles |
Dr. Denis A Evseenko Dr. |
Basic Biology V |
Promoting survival and countering hypertrophy of pluripotent stem cell (PSC)-derived chondrocytes |
$411,330 |
University of California, San Diego |
Miles F Wilkinson |
Basic Biology V |
New Regulators of Spermatogonial Stem Cells: RHOX Homeobox Transcription Factors |
$552,811 |
University of California, Los Angeles |
Dr. Lili Yang |
Basic Biology V |
Differentiation of Human Hematopoietic Stem Cells into iNKT Cells |
$614,400 |
University of California, San Diego |
Dr. Cornelis Murre |
Basic Biology V |
Epigenetic mechanisms that enforce pluripotency in embryonic stem cells |
$1,160,997 |
University of California, San Diego |
Dr. Wei Wang |
Basic Biology V |
Systems-level discovery of the regulatory mechanisms directing differentiation of hESC |
$1,161,000 |
University of California, San Diego |
Dr. Lawrence S. B. Goldstein |
Basic Biology V |
Elucidating pathways from hereditary Alzheimer mutations to pathological tau phenotypes |
$1,050,300 |
University of California, San Diego |
Dr. David A. Cheresh |
Basic Biology V |
CD61-driven stemness program in epithelial cancer |
$1,161,000 |
University of California, Berkeley |
Dr. Andrew Dillin |
Basic Biology V |
A Requirement for Protein Homeostasis in the Mediation of Stem Cell Health |
$1,034,100 |
Stanford University |
Xinnan Wang |
Basic Biology V |
Misregulated Mitophagy in Parkinsonian Neurodegeneration |
$1,174,943 |
University of Southern California |
Dr. Mark S Humayun |
Disease Team Therapy Development III |
Phase 1 Safety Assessment of CPCB-RPE1, hESC-derived RPE Cell Coated Parylene Membrane Implants, in Patients with Advanced Dry Age Related Macular Degeneration |
$16,339,827 |
University of California, Davis |
Dr. Peter C. Belafsky |
Disease Team Therapy Development III |
Tissue Engineered Recellularized Laryngotracheal Implants |
$3,181,162 |
University of California, Los Angeles |
Dr. Dennis J Slamon |
Disease Team Therapy Development III |
A Phase I dose escalation and expansion clinical trial of the novel first-in-class Polo-like Kinase 4 (PLK4) inhibitor, CFI-400945 in patients with advanced solid tumors |
$5,683,693 |
Stanford University |
Professor Irving L Weissman MD |
Disease Team Therapy Development III |
Clinical Investigation of a Humanized Anti-CD47 Antibody in Targeting Cancer Stem Cells in Hematologic Malignancies and Solid Tumors |
$6,505,568 |
University of California, Los Angeles |
Dr. Donald B. Kohn PhD |
Disease Team Therapy Development III |
Clinical Trial of Stem Cell Gene Therapy for Sickle Cell Disease |
$13,145,465 |